Arshad Khanani
Corporate Officer/Principal bij Gyroscope Therapeutics Ltd.
Oorsprong van het eerstegraads netwerk van Arshad Khanani
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom.
9
| Subsidiary | Biotechnology | 9 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Arshad Khanani via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Eyebiotech Ltd.
 Eyebiotech Ltd. BiotechnologyHealth Technology Eyebiotech Ltd. is a British clinical stage ophthalmology company that treats patients with sight-threatening diseases. The company is based in London, UK. Eyebiotech was founded in 2021 by David R. Guyer and Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | Biotechnology | Founder Private Equity Investor | |
| ALLERGAN, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Orbit Biomedical Ltd.
 Orbit Biomedical Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2018, Orbit Biomedical Ltd. is a British biotechnology company that engages in research and development. Part of Novartis AG, the company is based in Stevenage, UK. | Miscellaneous Commercial Services | Director/Board Member | |
BridgeBio Pharma LLC
 BridgeBio Pharma LLC BiotechnologyHealth Technology BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA. | Biotechnology | Director/Board Member | |
| JAZZ PHARMACEUTICALS PLC | Pharmaceuticals: Major | Director/Board Member | |
Ambys Medicines, Inc.
 Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| University of Wisconsin | College/University | Undergraduate Degree | |
| The University of California, San Francisco | College/University | Doctorate Degree | |
| OLEMA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Altrubio, Inc.
 Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | Internet Retail | Director/Board Member | |
Howard Hughes Medical Institute, Inc.
 Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| University of Aston | College/University | Graduate Degree | |
| University of Wolverhampton | College/University | Undergraduate Degree | |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
One Bio, Inc.
 One Bio, Inc. BiotechnologyHealth Technology One Bio, Inc. is an American biotechnology company that was founded in 2023. The CEO is Khurem Farooq. | Biotechnology | Chief Executive Officer | |
| University of Oxford | College/University | Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree | |
| Harvard Medical School | College/University | Doctorate Degree | |
The Methodist Hospital
 The Methodist Hospital Hospital/Nursing ManagementHealth Services The Methodist Hospital owns and operates general medical hospitals. The firm provides services for cancer, gastroenterology and GI surgery, neurology and neurosurgery, orthopedics, and sports medicine and transplant. The company was founded in 1919 and is headquartered in Houston, TX. | Hospital/Nursing Management | Chairman | |
| Retina Consultants of Houston PA | Chief Tech/Sci/R&D Officer | ||
Infocus Capital Partners
 Infocus Capital Partners Investment ManagersFinance InFocus Capital Partners (InFocus Capital Partners) is a venture capital firm founded in 2016 by Rob Rothman and Ron Weiss. The firm is headquartered in Jericho, New York. | Investment Managers | Consultant / Advisor | |
Solas Bioventures (mayfield) LLC
 Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | Investment Managers | Consultant / Advisor | |
| Tuck School of Business at Dartmouth | College/University | Masters Business Admin | |
| Geisel School of Medicine | College/University | Doctorate Degree | |
| BRIDGEBIO PHARMA, INC. | Biotechnology | Director/Board Member | |
| Haas School of Business | College/University | Masters Business Admin | |
| DENALI THERAPEUTICS INC. | Biotechnology | Director/Board Member | |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Pharmaceuticals: Generic | Chief Executive Officer | |
Oxular Ltd.
 Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Chairman | |
| NIGHTSTAR THERAPEUTICS PLC | Pharmaceuticals: Major | Chief Executive Officer | |
Johnson & Johnson Vision Care, Inc.
 Johnson & Johnson Vision Care, Inc. Electronic ComponentsElectronic Technology Johnson & Johnson Vision Care, Inc. manufactures and markets vision care products. The company was founded on March 07, 1962 and is headquartered in Jacksonville, FL. | Electronic Components | Corporate Officer/Principal | |
| Glaucoma Foundation | Director/Board Member | ||
| Butler University | College/University | Undergraduate Degree | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
| TERNS PHARMACEUTICALS, INC. | Biotechnology | Chairman | |
| Jaguar Therapeutics | Director/Board Member | ||
| Arctos Medical | Director/Board Member | ||
Axovia Therapeutics, Inc.
 Axovia Therapeutics, Inc. BiotechnologyHealth Technology Part of Axovia Therapeutics Ltd., Axovia Therapeutics, Inc. is dedicated to developing disease-transformative therapies that target key aspects of ciliopathies. The American company is working to advance gene therapy programs that have already shown early promise in treating some of the most severe aspects of bbs, such as early onset blindness and neurometabolic disease. The company was founded by Philip Beales, Victor Hernandez, and Philip Beales has been the CEO since incorporation. Axovia Therapeutics was acquired by Alsa Management Services Ltd on September 19, 2023. | Biotechnology | Director/Board Member | |
Jaguar Gene Therapy LLC
 Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a clinical stage biotechnology company based in Lake Forest, IL. Jaguar Gene Therapy LLC is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company has a proven team of experts who have experience in bringing novel gene therapy treatments to patients and their families. Jaguar is rapidly advancing an initial pipeline of three programs, including targeting severe neurodevelopmental disorders, type 1 galactosemia, and type 1 diabetes. The company partner with Advanced Medicine Partners for manufacturing their therapeutics. Key investors include Deerfield Management Company, Arch Venture Partners, and Eli Lilly and Company. The company was founded by Daniel Gallo, and Joseph Nolan has been the CEO since 2020. | Medical/Nursing Services | Director/Board Member | |
Allergan Ltd.
 Allergan Ltd. Pharmaceuticals: MajorHealth Technology Allergan Ltd. provides eye care and specialty pharmaceutical products. It develops pharmaceutical products used for treatment of eye and skin care medications and neurological disorders. The firm develops products for glaucoma, dry eye, blepharospasm, cervical, dystonia, hemi-facial spasm, post-stroke spasticity and cerebral palsy. The company was founded in 1977 and is headquartered in Marlow, the United Kingdom. | Pharmaceuticals: Major | President | |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| University of Illinois | College/University | Undergraduate Degree | |
(OSI) Eyetech
 (OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| Pritzker School of Medicine | College/University | Doctorate Degree | |
| Retinal Degeneration Fund | Director/Board Member | ||
| EYEPOINT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 34 |
| Verenigd Koninkrijk | 13 |
| Ierland | 2 |
| Zwitserland | 2 |
| Australië | 2 |
Sectoraal
| Health Technology | 22 |
| Consumer Services | 13 |
| Finance | 4 |
| Health Services | 4 |
| Commercial Services | 3 |
Operationeel
| Director/Board Member | 36 |
| Corporate Officer/Principal | 11 |
| Chief Executive Officer | 8 |
| Undergraduate Degree | 7 |
| Independent Dir/Board Member | 6 |
Sterkste connecties
| Insiders | |
|---|---|
| David Fellows | 16 |
| Jennifer Cook | 13 |
| Anthony Adamis | 12 |
| Sean Bohen | 9 |
| Khurem Farooq | 8 |
| Charles C. Wykoff | 7 |
| Baker Keith | 6 |
| Ian Clark | 1 |
| Peter Lachmann | 1 |
- Beurs
- Insiders
- Arshad Khanani
- Bedrijfsconnecties
